Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onivyde and Metronomic Temozolomide in Recurrent Glioblastoma
NCT03119064Phase 2Terminated
- Sponsor
- Brown University
- Start
- Nov 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in glioblastoma (GBM), sponsored by Brown University. Started Nov 2017; status: terminated.
02
Drugs
irinotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03119064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119064.